New drug before breast cancer surgery
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new drug, QL1706, given alongside chemotherapy before surgery for a certain type of breast cancer. It aims to see if this combination helps shrink tumors before they are removed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman aged 18 or older and are scheduled to have surgery for breast cancer.
- Your breast cancer is hormone receptor-positive (HR+) and HER2-negative, with a high Ki67 score (≥20%).
- You have not had any previous chemotherapy, radiation, or other cancer drugs for this breast cancer.
- Your tumor is stage cT2-T4d with or without lymph node involvement, or it is stage cT1c with confirmed spread to lymph nodes.
- Your overall health is good (ECOG score 0-1) and your organs are functioning well enough for treatment.
- You are willing to provide a tumor tissue sample and use effective birth control if you are premenopausal.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two combinations of drugs given before surgery to shrink HER2-positive breast cancer. One uses a new experimental drug (TQB2102) and the other uses standard treatments. The goal is to see which works better at reducing the cancer before surgery.
This trial tests a new drug combination given before surgery for early-stage, hormone receptor-positive breast cancer. It aims to see if this approach can improve outcomes for patients with high-risk features.
This trial tests a combination of targeted drugs and chemotherapy before surgery for HER2-positive breast cancer. It aims to see if this approach can shrink or eliminate the tumor, making surgery more effective.
This trial tests a new immunotherapy combination with chemotherapy given before breast cancer surgery, to shrink the tumor and improve outcomes. It's for people with early-stage triple-negative breast cancer whose tumors are larger than 2 cm.
This trial tests a new drug (SHR-A1811) alone or with letrozole given before surgery to shrink early-stage breast cancer that is hormone receptor-positive and HER2-low. It may help make surgery more effective.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.